HIT to LEAD to Preclinical Candidate development of a Transcription Repressor Inhibitory Compound (TRIC) that increases antibiotic susceptibility of multidrug resistant staphylococci

Description

A new and highly innovative treatment will be realized by a novel and patentable small molecule combinatorial drug candidate for the treatment of antibiotic resistance in multi-resistant, pathogenic staphylococci. The consortium integrates a screening platform, biophysical characterization of small molecules, medicinal chemistry, high-end characterization of mode of action and the in vivo mouse models, to develop initial HIT compounds into preclinical candidates.